Background {#Sec1}
==========

Osteonecrosis of the femoral head (ONFH) is mainly associated with significant hip pain and dysfunction in young adults. ONFH was reported to affect 20,000 patients each year in America \[[@CR1]\]. The estimated yearly incidence of ONFH in Korea is 37.96/100000 \[[@CR2]\]. Most patients without an effective treatment in the early stage require hip joint replacement. About 49% of untreated asymptomatic ONFH hips progressed to collapse at 49 months following diagnosis \[[@CR3]\]. Postcollapse ONFH is one of the most common reasons for primary total hip arthroplasty in many countries \[[@CR2], [@CR4]\]. Given the relatively young age at the time of presentation, it is reasonable to preserve the native hip in patients with early-stage ONFH. Several different joint-preserving operative interventions have been reported with promising outcomes in the past decades, including core decompression, osteotomy, and vascularized/nonvascularized bone grafting.

Unlike those operative interventions, biophysical therapy is considered as a noninvasive method for ONFH treatment \[[@CR5]\]. Biophysical techniques such as extracorporeal shock wave therapy (ESWT) have also been reported to enhance bone formation and preserve the femoral head in osteonecrosis \[[@CR6], [@CR7]\]. The use of ESWT in the field of orthopedics started in the 1990s, and the main indications were calcified tendonitis, heel pain, and fracture nonunion \[[@CR8]\]. In 2001, the first report on ESWT for ONFH showing promising short-term results was published \[[@CR6]\]. Subsequently, a randomized controlled trial showed that ESWT was more effective than core decompression and nonvascularized bone grafting for early-stage ONFH treatment \[[@CR7]\]. Some good-to-excellent outcomes in pain relief, functional improvement, and hip survival have been reported in the past decade \[[@CR9]--[@CR13]\]. However, the long-term outcomes of ESWT for ONFH remain unknown. Therefore, the objective of this study was to determine the long-term outcomes of ESWT for ONFH.

Methods {#Sec2}
=======

The current retrospective study was approved by our institutional review board. Fifty-three hips in 39 consecutive patients underwent ESWT in our hospital between January 2005 and July 2006. Written informed consent was obtained for each patient who participated in the current study according to our institutional policy. The diagnosis of nontraumatic ONFH was based on history, clinical examination, and imaging assessment. The inclusion criteria were patients with symptomatic early-stage ONFH, which was defined as Association Research Circulation Osseous (ARCO) stages I--III ONFH with hip pain and/or dysfunction (Table [1](#Tab1){ref-type="table"}), \[[@CR14], [@CR15]\]. The exclusion criteria were ONFH patients with the following: (1) former surgical treatment, (2) history of hip trauma, and (3) ARCO stage IV.Table 1Association Research Circulation Osseous classification of osteonecrosis \[[@CR14], [@CR15]\]StageFindingsSubclassificationQuantitation0All present techniques normalNoNoIRadiography and computed tomography normal; at least one of the other techniques is positiveLocation of lesion\
Medial\
Central\
LateralArea of involvement (%)\
A: \< 15%\
B: 15 to 30%\
C: \> 30%\
Length of crescent\
A: \< 15%\
B: 15% to 30%\
C: \> 30%\
Surface collapse and dome depression\
A: \< 15% and \< 2 mm\
B: 15% to 30% and 2 mm to 4 mm\
C: \> 30% and \> 4 mmIINo crescent sign;\
Sclerosis, osteolysis, focal porosisIIICrescent sign and/or flattening of articular surfaceIVOsteoarthritis, joint space narrowing, acetabular changes, joint destructionNoNo

The mean follow-up duration was 130.6 months (range, 121 to 138 months). Five hips in five patients with traumatic ONFH and two hips in one patient with ARCO stage IV ONFH were excluded. Two patients (two hips) were unable to participate in the current study due to personal reasons. Forty-four symptomatic nontraumatic ONFH hips in 31 patients (32 hips in 23 male patients and 12 hips in 8 female patients) with a mean age of 41.2 years (range, 22 to 60 years) were included in the current study (Table [2](#Tab2){ref-type="table"}). Sixteen patients with 24 hips were on a high-dose of corticosteroids. Seven patients with nine hips had a history of alcohol abuse. Eleven hips in eight patients with no established risk factor were considered as having idiopathic ONFH. According to the ARCO classification, eight hips were stage I, 28 hips were stage II, and the remaining were stage III.Table 2Characteristics of patientsCharacteristicTotalNumber of patients31Number of hips44Sex Male23 Female8 Mean age (year)41.2 Mean follow-up (month)130.6ARCO stage (hips) I8 II28 III8Risk factor (hips) Corticosteroid24 Alcoholic9 Idiopathic11

ESWT was performed by two senior doctors, under spinal anesthesia or general anesthesia. The patients were placed in the supine position on the radioparent operation table with the limbs secured to the table. The femoral artery was identified and marked on the skin to avoid direct shock during the procession of treatment. The lesion on the femoral head was identified using a C-arm (Siemens, Germany) in ARCO stage II and III patients before treatment. In stage I patients, the lesion was identified according to MRI. Four focal points were selected around the lesion under the C-arm to receive extracorporeal shock wave therapy with an OssaTron (HMT, Switzerland). Each point was treated with 1000 impulses of shock waves at 26 kV and 4 Hz. Treatment was performed bilaterally in 13 patients, and all hips received a single treatment. After treatment, the patient was asked to ensure strict no weight-bearing to limited weight-bearing in the first 3 months; full weight-bearing was allowed at 3 months postoperatively.

The visual analog pain scale (VAS), Harris hip score, and the radiography and magnetic resonance imaging (MRI) scans were collected before treatment and during the follow-up. Hip function was evaluated using the Harris hip score. The VAS was used to evaluate pain relief after treatment. Imaging examinations including standardized radiography and MRI were performed to evaluate the ARCO stage of the disease and the bone marrow edema (BME) of the femoral head. According to the range of edema, BME is divided into five grades: grade 0 for no BME, grade 1 for peri-necrotic BME, grade 2 for BME extending into the femoral head, grade 3 for BME extending into the neck of the femur, and grade 4 for BME extending into the intertrochanteric region \[[@CR10]\]. The results were classified as a clinical success (no progression of hip symptoms), an imaging success (no progression of stage or substage on the radiography and MRI), or failure (progression of hip symptoms or ARCO stage).

SAS version 8.0 (SAS Institute Inc., USA) was used to perform all statistical calculations. The outcomes at the final follow-up were compared with data before ESWT using the *t* test. A two-tailed *p* value of less than 0.05 was considered significant.

Results {#Sec3}
=======

The mean Harris hip score improved significantly from 77.4 before ESWT to 86.9 points at the 10-year follow-up (*p* \< 0.001). The mean VAS score decreased significantly from 3.8 preoperatively to 2.2 points at the final follow-up (*p* \< 0.001). The outcomes of ESWT were different in patients with different ARCO stages and pathogeny at the final follow-up (Table [3](#Tab3){ref-type="table"}). The clinical success was defined as no progression of hip symptoms, which was observed in 87.5% of ARCO stage I patients, 71.4% of ARCO stage II patients, and 75.0% of ARCO stage III patients. ESWT was most effective in patients with idiopathic ONFH. Four hips in ARCO stage III and one hip in ARCO stage II underwent total hip arthroplasty (THA) during the follow-up, because of aggravated disease with unacceptable pain and hip dysfunction. Three (two hips in ARCO stage IV and one hip in ARCO stage IIIc) underwent THA 1 year after ESWT, one (ARCO stage IV) at 2 years, and one (ARCO stage IV) at 5 years.Table 3Clinical outcome of patients with different ARCO stage and risk factorBefore ESWTFinal follow-up*P* valueTotal Harris hip score77.4 ± 15.186.9 ± 13.7\< 0.001 VAS3.8 ± 2.62.2 ± 2.4\< 0.001ARCO stageARCO stage I Harris hip score84.9 ± 12.496.6 ± 4.00.033 VAS2.9 ± 2.20.5 ± 0.80.015ARCO stage II Harris hip score80.2 ± 14.188.9 ± 11.90.005 VAS3.3 ± 2.61.8 ± 2.10.008ARCO stage III Harris hip score59.9 ± 6.770.2 ± 12.70.083 VAS6.5 ± 0.94.9 ± 2.50.155Risk factorCorticosteroid Harris hip score79.8 ± 15.587.2 ± 12.90.020 VAS3.5 ± 2.72.4 ± 2.50.063Alcoholic Harris hip score72.0 ± 19.078.4 ± 15.80.198 VAS4.4 ± 2.83.4 ± 2.50.201Idiopathic Harris hip score76.5 ± 10.393.3 ± 10.90.001 VAS4.0 ± 2.10.7 ± 0.8\< 0.001

All patients received imaging examinations before treatment and at the follow-up. Imaging success was observed in all stage I hips, 64.3% of stage II hips, and 12.5% of stage III hips. At the last follow-up, lesions in three stage I hips and one stage II hip could not be detected on MRI (Fig. [1](#Fig1){ref-type="fig"}). A total of 17 hips showed progression of the ARCO stage/substage on radiography or MRI. At the last follow-up, eight hips showed femoral head collapse on standardized radiographs (Table [4](#Tab4){ref-type="table"}). Five of them received THA during the follow-up; the three remaining patients used non-steroidal anti-inflammatory drugs to reduce hip pain. BME around the focal osteonecrosis was observed on MRI before ESWT in all hips included in the current study. Ten hips had grade 1 BME, 6 hips had grade 2 BME, 13 hips had grade 3 BME, and 15 hips had grade 4 BME before ESWT. A reduction in BME was also noted in 30 hips at the final follow-up. Thirteen hips showed no significant change in BME at the final follow-up (Fig. [2](#Fig2){ref-type="fig"}). Only one ARCO stage II hip with grade 2 BME progressed to grade 3. In patients with improved BME, the mean VAS score was 1.6 points at the 10-year follow-up, and the mean Harris hip score was 89.7 points at the 10-year follow-up. In patients with unchanged BME, the mean VAS score was 3.5 points and the mean Harris hip score was 79.8 points at the last follow-up. Clinical outcomes were better in the BME improved group than in the BME unchanged group (Table [5](#Tab5){ref-type="table"}).Fig. 1MRI of a young woman with high-dose corticosteroid use: **a** MRI indicated bilaterally ARCO stage II ONFH before ESWT; **b** MRI in 3 months after ESWT; **c** MRI in 5 years after ESWT; **d** No lesion was observed in MRI at final follow-up. The patient has fully hip function without pain at the final follow-upTable 4Change in MRI before ESWT and at 10-year follow-upImprovedUnchangedProgressedCollapsedARCO stage I Ia2500 Ib1000 Ic0000Total3500ARCO stage II IIa0110 IIb6331 IIc5362Total117103ARCO stage III IIIa0131 IIIb0011 IIIc0033Total0175Fig. 2MRI of a mid-age man with long-term alcohol abuse: **a** MRI indicated ARCO stage II ONFH with grade 4 BME in the left hip before ESWT; **b** BME reduction was observed in 3 months after ESWT; **c** MRI in 5 years after ESWT; **d** MRI indicated grade 2 BME at the final follow-up. The patient has restored hip function without pain since 5 months after ESWTTable 5Clinical outcome of patients with different BME changeBefore ESWTFinal follow-up*P* valueHarris hip scoreBME improved Total77.8 ± 15.689.7 ± 11.1\< 0.001 ARCO stage I84.6 ± 15.495.6 ± 4.50.175 ARCO stage II80.5 ± 14.391.1 ± 11.00.006 ARCO stage III60.4 ± 8.578.0 ± 9.10.045BME unchanged Total77.2 ± 15.179.8 ± 17.20.354 ARCO stage I85.3 ± 8.198.3 ± 9.10.157 ARCO stage II81.4 ± 14.581.6 ± 12.80.970 ARCO stage III59.0 ± 3.557.3 ± 1.20.560BME progressed Total67.096.0/ ARCO stage II67.096.0/VASBME improved Total3.8 ± 2.81.6 ± 1.8\< 0.001 ARCO stage I3.1 ± 2.70.8 ± 0.80.118 ARCO stage II3.3 ± 2.81.5 ± 1.90.005 ARCO stage III6.5 ± 1.13.3 ± 1.20.019BME unchanged Total3.7 ± 2.23.5 ± 3.20.734 ARCO stage I2.5 ± 1.50 ± 00.102 ARCO stage II3.0 ± 1.93.1 ± 2.40.873 ARCO stage III6.4 ± 0.47.6 ± 0.60.148BME progressed Total5.51.5/ ARCO stage II5.51.5/

Discussion {#Sec4}
==========

The current study showed that significant improvements in pain relief and function restoration were maintained for more than 10 years after ESWT. The mean Harris hip score improved from 77.4 before ESWT to 86.9 points at the final follow-up. The mean VAS score decreased from 3.8 preoperatively to 2.2 points at the 10-year follow-up. Four ARCO stage III hips and one ARCO stage II hip underwent THA during the follow-up due to unacceptable pain and hip dysfunction. The improvement of clinical assessments in our study was comparable with those in former short and mid-term reports \[[@CR6], [@CR7], [@CR9]--[@CR12]\]. In patients with clinical success, pain relief and functional restoration often occurred between 3 months and 1 year after ESWT and were maintained for more than 10 years. The exacerbation of symptoms would appear at 5 months to 10 years after treatment. We consider it necessary to evaluate the affected hip once every year after ESWT.

According to imaging assessments, 14 hips (31.8%) showed improved images with decreased lesion size, and 13 hips (29.5%) showed no significant change in ARCO stage/substage. Seventeen hips (38.6%) showed progression of the ARCO stage, and eight hips (18.1%) showed femoral head collapse on standardized radiographs at the last follow-up. According to imaging assessments, ESWT could prevent progression of the disease in ARCO stage I and II hips. For ARCO stage III hips, a significant progression of the disease was observed during the follow-up. A significant reduction in BME was also noted in most hips at the 10-year follow-up. BME of the proximal femur could be commonly detected by MRI in patients with symptomatic ONFH. BME could increase the bone marrow pressure, which may reduce the blood supply and promote avascular necrosis of the femoral head \[[@CR16]\]. A former study by Koo et al. showed that BME of the proximal femur was strongly related to joint pain in patients with early-stage ONFH \[[@CR17]\]. Huang et al. analyzed radiograph and MRI scans of 71 ONFH patients and found that 98% of osteonecrotic hips with BME were painful \[[@CR18]\]. ESWT has been reported to be effective for the treatment of BME in ONFH patients \[[@CR9], [@CR10]\]. In our study, the clinical outcomes in patients with BME reduction are superior to those in other patients, which indicated that physical decompression caused by BME reduction is beneficial to ONFH patients.

The aim of early-stage ONFH treatment is to prevent collapse by delaying the natural progression of the disease. Several joint-preserving operative interventions have been used in the past decade. Given their unpredictable long-term clinical outcomes, none of these methods is generally optimal. Core decompression is the most common joint-preserving operation for early-stage ONFH treatment worldwide. However, several systematic reviews and meta-analyses indicated that core decompression did not provide a significant difference in the collapse rate when compared with other joint-preserving treatments \[[@CR19]--[@CR21]\]. Wang et al. compared the outcome between ESWT and core decompression with bone grafting. ESWT had better clinical outcomes in terms of pain relief, function restoration, and THA rate when compared with core decompression \[[@CR9]\]. The present study findings suggest promising long-term results of ESWT for early-stage ONFH.

Several studies also reported that ESWT was more effective in early-stage ONFH (ARCO stage I and II) \[[@CR7], [@CR10], [@CR11]\]. Our study confirmed that ARCO stage III patients benefit less from ESWT than ARCO stage I and II patients. The 10-year survival of ARCO stage III hips was 50%, which was also inferior to that of other groups. Based on the information now available, we suggest that further randomized controlled trial studies should be performed to confirm the effectiveness of ESWT for patients with ARCO stage I and II ONFH.

A former study analyzed the outcome of ESWT for ONFH in systemic lupus erythematosus (SLE) patients with corticosteroid use \[[@CR22]\]. Both SLE and non-SLE patients showed a significant improvement in the clinical outcome and imaging studies, and no statistically significant differences were observed between the two groups. Because of the limited number of patients, we are still unable to determine whether different pathogenies could affect the treatment outcome of ESWT. The mean Harris hip score (78.4) and mean VAS score (3.4) in patients with alcohol abuse were inferior to those in patients with corticosteroid-related and idiopathic ONFH at the final follow-up. However, more than half (five of nine hips) of the alcoholic patients had ARCO stage III hips. As we mentioned above, ARCO stage III ONFH is often associated with a poor outcome after ESWT.

As a non-invasive treatment method, ESWT has been reported as an effective treatment method for musculoskeletal diseases since the 1990s. However, the true treatment mechanism of ESWT for pain relief and tissue remolding has not been fully understood. Wang et al. reported that ESWT promoted bone healing by increasing neovessels and upregulated growth factors at the tendon-bone junction \[[@CR23]\]. Immunohistochemical examination indicated that ESWT upregulates the expression of vWF, VEGF, and CD31 in the human femoral head \[[@CR24]\]. Localized hematoma and cell death caused by direct shock could also promote new bone formation \[[@CR25]\]. Several animal studies indicated that the pain relief with ESWT could be owing to diminished pain transmission to the central nervous system. The stimulation of the extracorporeal shock wave to the distal femur could decrease the release of substance P after 6 weeks in rabbits \[[@CR26]\]. Moreover, in the dorsal root ganglion of rabbits, neurons immunoreactive for substance P were depressed after extracorporeal shock wave treatment to the distal femur \[[@CR27]\]. Based on our results, we hypothesize that the significant pain relief in ONFH patients after ESWT is based on BME reduction. The physical decompression caused by BME reduction would increase the blood supply in focal lesions.

The current study has several limitations that should be acknowledged. First, the current study is limited by its retrospective design. Second, the limited number of participants may have caused bias in the assessment of the outcomes. Third, there was no control group. A comparison between ESWT and other treatments would be useful to determine the superiority of ESWT in the treatment of ONFH in well-selected patients.

Conclusions {#Sec5}
===========

In summary, ESWT is an effective treatment method for early-stage nontraumatic ONFH. Significant improvements including pain relief and functional restoration were maintained for more than 10 years after treatment. More large-scale randomized controlled trial studies should be performed to confirm the effectiveness of ESWT for early-stage nontraumatic ONFH.
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